Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule
We are pioneering safe innovative and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. We focus to alleviate disease while restoring homeostasis through multiple concerted molecular pathways.
Our Science20+
scientists and researchers
8
drug candidates in development
20+
patents filed
Your health is our mission. With decades of expertise behind us, we’re at the forefront of developing novel therapies that make a real difference. Our team’s deep rooted knowledge fuels our commitment to pioneering research and bringing safe, effective treatments to you as swiftly as possible. We’re dedicated to transparency and results, ensuring every breakthrough is a beacon of hope for your healthier tomorrow.
For PatientsOvid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule
July 01, 2024
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
February 01, 2024
ROCK2 regulates microglia proliferation and neuronal survival after traumatic brain injury
January 10, 2024
Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors
January 02, 2024